| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_390be8b40737dd62f57f366e17a9af5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_053853e8d9494b450703b1f2681a187b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57977c1a8aeff9211f97ab7f688d0107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b0977fbdebe19b7df92cb7e69669082 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-683
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-683
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-51 |
| filingDate |
2001-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10ab61174d23b19dedfbd0cbf68e5a4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac8f92ca34d77e870672117bfa12a42e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_681889d9cd1be1ab6216749ec5e99da5 |
| publicationDate |
2002-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0227019-A8 |
| titleOfInvention |
Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
| abstract |
The present invention provides methods relating to chemotherapeutic treatment of a cell proliferative disorder. In particular, a method is provided for predicting the clinical response to certain types of chemotherapeutic agents. Aklylating agents, used for the treatment of certain types of tumors including tumors of the nervous system and lymph system, are efficacious agents when the damage they do to tumor cell DNA is not repaired by cellular DNA repair mechanisms. The present invention provides a method for determining the activity of a gene encoding a DNA repair enzyme, thus providing a prediction of the clinical response to alkylating agents. Figure (1) shows the overall survival among subjects with gliomas treated carmustine, and the time of progression of disease according to the methylation status of the MGMT promoter. |
| priorityDate |
2000-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |